These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 38551948

  • 1. Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists.
    Koizumi M, Ishimoto T, Shimizu S, Sasaki S, Kurita N, Wada T.
    PLoS One; 2024; 19(3):e0299053. PubMed ID: 38551948
    [Abstract] [Full Text] [Related]

  • 2. Practice patterns of rituximab for primary membranous nephropathy 2021 in Japan: a web-based survey of board-certified nephrologists.
    Miyaoka Y, Kurita N, Sofue T, Nishiwaki H, Koizumi M, Shimizu S, Sasaki S, Ishimoto T, Wada T.
    Clin Exp Nephrol; 2024 Mar; 28(3):217-224. PubMed ID: 37924431
    [Abstract] [Full Text] [Related]

  • 3. Japanese clinical practice patterns of primary nephrotic syndrome 2021: a web-based questionnaire survey of certified nephrologists.
    Wada T, Shimizu S, Koizumi M, Sofue T, Nishiwaki H, Sasaki S, Nakaya I, Oe Y, Ishimoto T, Furuichi K, Okada H, Kurita N.
    Clin Exp Nephrol; 2023 Sep; 27(9):767-775. PubMed ID: 37310570
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J, Zhao H, Li X, Qian R, Gao P, Lu S, Ma Z.
    BMC Nephrol; 2023 Apr 26; 24(1):112. PubMed ID: 37101300
    [Abstract] [Full Text] [Related]

  • 5. Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease.
    Heybeli C, Erickson SB, Fervenza FC, Hogan MC, Zand L, Leung N.
    Nephrol Dial Transplant; 2021 Sep 27; 36(10):1821-1827. PubMed ID: 32918483
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S, Ohtake T, Mochida Y, Ishioka K, Moriya H, Hidaka S, Kobayashi S.
    Clin Exp Nephrol; 2020 Dec 27; 24(12):1132-1139. PubMed ID: 32761467
    [Abstract] [Full Text] [Related]

  • 7. Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologists' questionnaire survey.
    Niihata K, Nishiwaki H, Kurita N, Okada H, Maruyama S, Narita I, Shibagaki Y, Nakaya I.
    Clin Exp Nephrol; 2019 Nov 27; 23(11):1288-1297. PubMed ID: 31385161
    [Abstract] [Full Text] [Related]

  • 8. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M.
    Am J Nephrol; 2014 Nov 27; 39(4):322-30. PubMed ID: 24751753
    [Abstract] [Full Text] [Related]

  • 9. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N.
    BMC Nephrol; 2020 Apr 15; 21(1):134. PubMed ID: 32293308
    [Abstract] [Full Text] [Related]

  • 10. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L, Wang W, Wu Y, Xie J, Li X, Pan X, Zhang W, Xu J, Cai Y, Ren H, Chen N.
    Drug Des Devel Ther; 2021 Apr 15; 15():1945-1953. PubMed ID: 34007154
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of rituximab in adult frequently relapsing minimal change disease.
    King C, Logan S, Smith SW, Hewins P.
    Clin Kidney J; 2017 Feb 15; 10(1):16-19. PubMed ID: 28638601
    [Abstract] [Full Text] [Related]

  • 12. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
    Papakrivopoulou E, Shendi AM, Salama AD, Khosravi M, Connolly JO, Trompeter R.
    Nephrology (Carlton); 2016 Oct 15; 21(10):893-900. PubMed ID: 26860320
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A, König P, Busch M, Wolf G, Mayer G, Rudnicki M.
    Wien Klin Wochenschr; 2013 Jun 15; 125(11-12):328-33. PubMed ID: 23624956
    [Abstract] [Full Text] [Related]

  • 14. Case report: Effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult.
    Wang Q, Lin L, Zhen J, Jiang B, Liu G.
    Front Immunol; 2024 Jun 15; 15():1407461. PubMed ID: 39136030
    [Abstract] [Full Text] [Related]

  • 15. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
    AlSahow A, Al-Muhaiteeb A, Nawar H, AlHelal B, AlYousef A, Abdallah E, AbuShall A, Elmekawi S, Meshal B, AlQallaf A, AlRajab H.
    Med Princ Pract; 2022 Jun 15; 31(2):133-141. PubMed ID: 35021170
    [Abstract] [Full Text] [Related]

  • 16. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E, Stahl RA, Harendza S.
    Clin Nephrol; 2011 Aug 15; 76(2):151-8. PubMed ID: 21762648
    [Abstract] [Full Text] [Related]

  • 17. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.
    Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K.
    Pediatr Nephrol; 2010 Mar 15; 25(3):539-44. PubMed ID: 20049616
    [Abstract] [Full Text] [Related]

  • 18. Survey of Japanese nephrologists' use of clinical practice guidelines for rapidly progressive glomerulonephritis.
    Takahashi-Kobayashi M, Sada KE, Kawashima S, Miyawaki Y, Nakazawa D, Furuichi K, Okada H, Narita I, Usui J.
    Clin Exp Nephrol; 2024 Apr 15; 28(4):316-324. PubMed ID: 38151607
    [Abstract] [Full Text] [Related]

  • 19. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K, Kagaya Y, Kumano S, Fujii A, Tsuruyama Y, Matsuura T, Yamazaki K, Nomura K, Okada K, Okino K, Adachi H, Furuichi K, Yokoyama H.
    Clin Nephrol; 2021 Jan 15; 95(1):29-36. PubMed ID: 33074094
    [Abstract] [Full Text] [Related]

  • 20. Rituximab use in adult glomerulopathies and its rationale.
    Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, Amoedo M, Pires C.
    J Bras Nefrol; 2020 Mar 15; 42(1):77-93. PubMed ID: 31904761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.